Drug intelligence / Profile preview

CART-HER-2

Development stage: Phase 2
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CART-HER-2 is a genetically engineered lymphocyte therapy, specifically a CAR-T cell therapy, designed to treat advanced HER-2 positive solid tumors that are refractory to chemotherapy and HER-2 antibody inhibitor therapy. It involves transducing autologous T cells with an anti-HER-2 vector, which includes CD137 and CD3 zeta signaling domains, to create chimeric antigen receptor T cells (CART-HER-2 cells). These engineered T cells are intended to recognize and kill cancer cells expressing the Human Epidermal Growth Factor Receptor-2 (HER-2) antigen.

Other names: anti-HER2 chimeric antigen receptor T cell therapyanti-HER-2 chimeric antigen receptor T cell therapyanti-HER 2 chimeric antigen receptor T cell therapyHER2-specific CAR-T cellsHER-2-specific CAR-T cellsHER 2-specific CAR-T cells

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CART-HER-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CART-HER-2.

Explore the full profile